X

Trial Profile

Effects of Everolimus (Certican) on cardiac hypertrophy and carotid atherosclerosis after kidney transplantation

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 04 May 2017

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Everolimus (Primary) ; Basiliximab; Mycophenolate sodium; Prednisone; Tacrolimus
Indications Carotid artery diseases; Left ventricular hypertrophy; Renal transplant rejection
Focus Pharmacodynamics
Sponsors Novartis

Most Recent Events

03 May 2017 Results presented at the 2017 American Transplant Congress
03 May 2017 Status changed from recruiting to completed, according to the results presented at the 2017 American Transplant Congress
17 Feb 2014 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com